




TACO

Tri-weekly Administration of Cisplatin in Locally Advanced Cervical Cancer KGOG



Trial setting: Locally advanced cervical cancer Stage IB2, IIB-IVA

Study Design: Weekly versus Tri-weekly Cisplatin based CRT

Sponsor(s): KGOG

Planned No. of patients: 374

Current accrual: 276


Collaboration

1. KGOG 14-> 5 sites
2. Ramathibodi Hospital (Thailand)
3. Ho Chi Minh Cancer Center (Vietnam)
4. Zheijiang Cancer Center (China)



TACO

Tri-weekly Administration of Cisplatin in Locally Advanced Cervical Cancer KGOG



Trial setting: Locally advanced cervical cancer Stage IB2, IIB-IVA

Study Design: Weekly versus Tri-weekly Cisplatin based CRT

Sponsor(s): KGOG


Planned No. of patients: 374

Current accrual: 276

Revision of accrual; 590-> 374 (2017.11)

Collaboration

1. KGOG 14-> 5 sites
2. Ramathibodi Hospital (Thailand)
3. Ho Chi Minh Cancer Center (Vietnam)
4. Zheijiang Cancer Center (China)



Accrual of TACO

Global

**Target 374
Accrual 267**

